Two videoconferences will take place today, September 4, 2024:
the first in French at 10:30 CEST and the second in English at 15:30 CEST / 9:30 EDT.
To participate, please register on these links:
– Videoconference in French: https://app.livestorm.co/p/29a18fe3-075a-4844-8cf9-21661d9c92bc
– Videoconference in English: https://app.livestorm.co/p/1c047cfb-8f68-49c0-bf37-3415852a2995
Bordeaux, France, September 4, 2024 – 7:00 AM CEST – Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases, announces results from the Phase 2B clinical study of AEF0117, evaluating its efficacy and safety in treatment-seeking participants with moderate to severe cannabis use disorder (CUD) who used cannabis at least ≥5 days/week at the time of study entry. In this study, 82% of participants had severe grade CUD according to the DSM-5 classification.
To receive all the financial information of AELIS FARMA in real time, please request it by e-mail to [email protected]. Your registration will be immediate.